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Abstract
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis (Mtb), is the main cause 
of death due to an infectious disease. After more than 100 years of the discovery of Mtb, 
clinicians still face difficulties finding an effective treatment for the increasing number of 
drug-resistant cases. The difficulties in the clinical setting can be related to the slow pace at 
which the understanding of the physiology of this bacterium has occurred. Mtb is distinct 
from other microorganisms not only due to its slow growth and difficulties to study in the 
laboratory, but also due to its inherent physiology such as its complex cell envelope and its 
metabolic pathways. Understanding the physiology of drug susceptible and resistant Mtb 
strains is crucial for the design of an effective chemotherapy against TB. This chapter will 
review the mycobacterial cell envelope and major physiological pathways together with 
recent discoveries in Mtb drug resistance through different “omics” disciplines.
Keywords: drug resistance, physiology, systems biology, proteomics, genomics, lipidomics
1. Introduction
The history of tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb), has 
a remarkable involvement in human history; particularly in the evolution of human society 
and in the development of many scientific disciplines. TB has a negative role in many pages 
of human history, taking lives of many renowned artists, politicians, as well as poor, wealthy, 
young, or adult individuals. After its apparent “resurgence” at the end of the last century with 
the concomitant arises of HIV/AIDS cases, TB has been mainly associated with poverty and 
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immunosuppression. Mtb was the model microorganism that inspired Koch to develop his 
postulates which are a cornerstone of sciences such as Microbiology and Immunology. What 
Robert Koch never probably imagined was that over a century later, this disease was going 
to continue as the leading cause of death, mostly because of the increasing number of drug-
resistant TB cases. Regarding TB treatment, it is discouraging to see how this lethal disease only 
started to be cured and controlled during 1950s with the discovery of the first chemotherapy. 
It is hard to imagine the labor of a clinician taking care of TB patients before 1950s without an 
available treatment option. However, this same scenario is similar to what many health provid-
ers face nowadays with the current spreading of drug-resistant cases, particularly multidrug 
resistant (MDR) and extensively drug resistant (XDR) TB cases. The majority of drug-resistant 
Mtb strains found in clinical settings emerge due to mutations in genes that are involved in the 
antibiotic mode of action (drug activator, drug target, etc.). These bacterial genes have impor-
tant roles in bacterial metabolism and pathogenicity. Therefore, the study of drug-resistant Mtb 
strains has been evolving from the exploration of the associated genotype (i.e. specific resis-
tance-conferring and compensatory mutation(s)) to the entire phenotypic impact that muta-
tion events confer to the bacteria beyond the drug resistance feature. The study of the global 
drug-resistant phenotype in Mtb thorough comprehensive system biology approaches (such as 
genomics, proteomics, and lipidomics) is expected to reveal important aspects that will help 
TB researchers in the development of new anti-TB chemotherapies and overcome the current 
global challenges toward an effective TB control. This chapter will describe an overview of Mtb 
physiology and metabolic pathways as an important scaffold to understand the physiological 
changes that some Mtb strains (specific genotypes) undergo after acquiring resistance to the 
major anti-TB drugs: isoniazid (INH) and rifampicin (RIF) from a biochemical perspective.
2. Review of Mtb major metabolic pathways and cell envelope
Mtb physiology is a broad subject comprising the study of the function and activities of this bac-
terium and its parts. In this chapter, we will narrow the study of Mtb physiology to its major 
metabolic pathways and cell envelope, particularly in the context of drug resistance.
2.1. Major central metabolic pathways in Mtb
Mtb has the ability to use very variable carbon sources in vitro such as carbohydrates, alco-
hols, and lipids (including cholesterol and fatty acids) (reviewed in Ref. [1]). Similar to other 
representative species of the Actinomycetales order, Mtb possesses a predominant aerobic 
metabolism, with the genes encoding for enzymes of the main energetic metabolic pathways 
such as glycolysis, tricarboxylic acid (TCA) cycle, and pentose phosphate pathway. Despite 
the genetic evidence of a complete TCA cycle in Mtb [2], there is no sufficient biochemical 
evidence to show the presence of all enzymatic reactions of the TCA cycle in Mtb. In fact, 
some researchers propose that TCA cycle in Mtb is not complete because this organism lacks 
the alpha ketoglutarate dehydrogenase (α-KDH) enzyme [3–5]. Instead, alpha ketoglutarate 
decarboxylase (α-KGD and Rv1248c) and succinic semialdehyde dehydrogenase (GabD1/2, 
Rv0234, and Rv1731, respectively) are proposed as the enzymes that catalyze the step from 
alpha ketoglutarate (α-KG) to succinate in Mtb TCA cycle under normoxic conditions. 
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Particularly, α-KGD catalyzes the production of succinic semialdehyde, which can then be 
converted to succinate by GabD1/2 [5]. Also, experimental evidence suggests that Mtb operates 
a reversed TCA cycle with the reduction of fumarate to succinate to maintain the membrane 
potential in the absence of oxygen [6].
Mtb also has the glyoxylate shunt which allows the bacteria to bypass some enzymes of the 
regular TCA cycle under specific metabolic conditions (hypoxia or growth on fatty acids as 
carbon source) [2]. Under anaerobic conditions, the enzyme isocitrate lyase (Icl) (which is 
proposed to be required for virulence [7]), together with the α-KG ferredoxin oxidoreductase 
are believed to complete the cycle effectively bypassing the conversions of α-ketoglutarate to 
succinate to fumarate [8].
Mtb has the ability to use enzymes in multiple metabolic pathways to prolong its survival, a fea-
ture that is known as metabolic plasticity. For instance, Icl not only participates in the glyoxylate 
shunt and the methyl citrate cycle but also protects Mtb from the oxidative stress generated by 
the treatment with isoniazid (INH), rifampicin (RIF), and streptomycin [9]. Another example is 
the dihydrolipoamide dehydrogenase (Lpd) that can act as the E3 component of the pyruvate 
dehydrogenase or can provide electrons to the dihydrolipoamide succinyltransferase (DlaT, pre-
viously known as SucB) or be part of the branched-chain keto acid dehydrogenase complex to 
metabolize branched-chain amino acids [9]. On the other hand, Mtb has pathways with redun-
dant enzymes (that include a variety of isozymes) that can catalyze the same reaction, which 
guarantees that vital processes occur despite possible external or internal stresses. A good 
example of this is the fatty acid degradation or β-oxidation pathway, which suggest that Mtb not 
only has a high lipid catabolism activity, but also that this is crucial part of its own metabolism [1].
2.2. Lipid metabolism: β-oxidation and fatty acid synthesis
Lipid metabolism is a highly relevant physiologic process in Mtb, with more than 6% of the 
genome devoted to these reactions and almost 20% of the genome encoding for genes related 
to cell wall processes. Lipid metabolism is an important part of this chapter as some enzymes 
of the lipid biosynthetic pathway are the target of anti-TB drugs such as INH and ethionamide. 
Compared to Escherichia coli, Mtb possess five times more enzymes dedicated to lipid metabo-
lism. Mtb lipid metabolism is more lipolytic than lipogenic, probably as a result of the wide 
variety and amount of lipid sources in the human host as well as in the bacterial envelope [2]. For 
this reason, the first part of this chapter will focus on fatty acid degradation with a subsequent 
description of recent findings regarding fatty acid synthesis. Fatty acid degradation is a key pro-
cess in Mtb metabolism and can explain some of its metabolic plasticity, while fatty acid synthesis 
is crucial in the understanding mechanism of action of the previously mentioned anti-TB drugs.
2.2.1. Fatty acid degradation
Fatty acid catabolism in Mtb is a process of successive oxidations where the β-carbon of the 
fatty acid is oxidized to a carbonyl group (Figure 1). In this process, the main goal is the syn-
thesis of acetyl-CoA and reduced cofactors (such as NADH, FADH
2
) that can fulfill energy 
requirements in the cell and also intermediates that can serve as substrate for anabolic pro-
cesses [2]. Specifically, odd-chain fatty acids produce acetyl-CoA while even-chain fatty acids 
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produce acetyl-CoA and propionyl-CoA in addition to acyl-CoA derivatives missing two car-
bon units [2, 10]. By studying the Mtb genome, Cole et al. found at least 35 genes encoding for 
enzymes that catalyze the first step of fatty acid degradation only. As shown in Figure 1, most 
reactions in this pathway can be carried out by several isozymes. Of these, EchA5 and FadB3 
are essential for Mtb growth and considered possible drug targets [11].
2.2.2. Fatty acid synthesis
The complexity of Mtb lipids can be partially explained by the fact that Mtb has both fatty acid 
synthases (FAS), type I and II. Cole et al. described the main enzymes of FAS I and II at the genetic 
level and recent reviews have compiled previous biochemical work, all of which have generated 
a better understanding of the complex pathways responsible for mycolic acid synthesis in Mtb 
[12–14]. The characterized enzymes that participate in FAS I and FAS II are shown in Table 1. 
FAS I is found mainly in eukaryotes and all the reactions are performed by a single multidomain 
homodimeric enzyme Fas (Rv2524) that has a mass higher than 300 kDa [2, 14]. This enzyme 
Figure 1. β-Oxidation of fatty acids in Mtb. Greek nomenclature indicates the different oxidations that take place in the 
β-carbon. The enzymes show the different number of identified isozymes that participate in this cycle.
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Description Gene Rv number Enzyme
FAS I fas 2524 Fatty acid synthetase
Transition FAS I to FAS II fabD 2243 Malonyl-CoA ACP transacylase
accD6 2247 Acetyl/propionyl-CoA carboxylase (beta subunit)
acpM 2244 Acyl carrier protein
fabH 0533 β-Ketoacyl-ACP synthase III
FAS II kasA/B 2245/2246 β-Ketoacyl-ACP synthase
fab1 or MabA 1483 β-Ketoacyl-ACP reductase
hadA/B/C 0635/0636/0637 (3)-hydroxyacyl-ACP dehydratase subunit A/B/C
htdX 0241 3-hydroxyacyl-thioester dehydratase
echA10/11 1142/1141 Currently annotated as a enoyl-CoA hydratase, but 
proposed to be 2-trans-enoyl-ACP isomerase
inhA 1484 2-trans-enoyl-ACP reductase
Modifications
Desaturases desA1/2/3 0824/1094/3229 Acyl carrier protein desaturase
Methyltransferases 
(methylation, oxygen 
function introduction and 
cyclopropanation)
mmaA1 0645c Methoxymycolic acid synthase 1
mmaA2 0644c Methoxymycolic acid synthase 2 (distal 
cyclopropane in α-MA, proximal cis-cyclopropane 
in keto-MA)
mmaA3 0643c Methoxymycolic acid synthase 3 (oxygenated MA)
mmaA4 0642c Methoxy mycolic acid synthase 4 (oxygenated MA)
cmaA1 3392c Cyclopropane-fatty-acyl-phospholipid synthase 1 
(distal position)
cmaA2 0503c Cyclopropane-fatty-acyl-phospholipid synthase 2 
(proximal position-specific in methoxy-MA)
Mycolic acid modification pcaA (umaA2) 0470c Mycolic acid synthase (proximal cyclopropanation 
function α-MA)
umaA 0469 Mycolic acid synthase
Clainsen-type 
condensation
accD4 3799c Acyl-CoA carboxylase
accD5 3280 Acyl-CoA carboxylase
fadD32 3801 Fatty-acid-AMP ligase
pks13 3800 Polyketide synthase-13
Mycolic acid processing mmpL3 0206 Transmembrane transport protein-3
Rv3802 3802 Proposed to be a Mycolyltransferase I, recently 
shown to have phospholipase and thioesterase 
activity
cmrA 2509 Reductase
fbpA/fbpB/
fbpC2
3804c/1886c/0129c Fibronectin-binding protein ABC or antigen 85 
complex
Table 1. Enzymes that participate in the FAS I and II pathways in Mtb.
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has seven catalytic domains: acyltransferase, enoyl reductase, dehydratase, malonyl/palmitoyl 
transferase, acyl carrier protein, β ketoacyl reductase, and β ketoacyl synthase [12]. Fas (Rv2524) 
uses acetyl-CoA and malonyl-CoA as substrates for the synthesis of acyl-CoA derivatives of 16 
and 18 carbon units which are in turn used for the synthesis of membrane phospholipids. FAS I 
route also produces an acyl-CoA derivative with 26 carbon units that becomes the short α-alkyl 
chain or α-branch of the mycolic acids. FAS I and II are connected by the synthesis of acyl-CoA 
derivatives with 20 carbon atoms that are used in the FAS II pathway as the starting molecule 
for the elongation of mycolic acids (reviewed in Ref. [14]).
There are important aspects to highlight regarding FAS I and II in Mtb. First, proteins FabD, 
AcpM, and FabH act in the transition between FAS I and FAS II, generating ACP deriva-
tives (the substrate required for the FAS II pathway). Second, there are two known Claisen-
type reactions occurring: one before the FAS II starts (responsible for the condensation of 
malonyl-ACP with acyl-CoA and catalyzed by FabH) and one shared with the polyketide 
synthase system (catalyzed by Pks13). The latter reaction generates a carbon-carbon bond 
between two activated fatty acids at the end of the mycolic acids synthesis. This second con-
densation takes the α-branch (produced through FAS I) and the longer meromycolate chain 
(produced through FAS I and II) to form a “pre-mature mycolic acid” [13, 14].
Regarding FAS II specifically, this pathway is involved in fatty acid elongation instead of de 
novo synthesis (contrary to what occurs in most bacteria, where FAS II has de novo synthe-
sis capacity) [12]. Mtb needs to use both FAS I and II to generate its characteristic mycolic 
acids [13, 14]. Therefore, the study of mycolic acids synthesis is in fact a study of both FAS 
pathways in Mtb. In FAS II, there is one different enzyme for each specific step, allowing 
for various levels of regulation. Most of the core enzymes of FAS II are NADPH or NADH 
dependent and organized in different clusters distributed through the genome (Figure 2 
and Table 1). FAS II can be further divided into type I and type II elongation (E1 FAS II and 
E2 FAS II, respectively). Here, both types are catalyzed by the core proteins InhA, MabA, 
HadABC, and FabD, and elongation can be done by either KasA (E1) or KasB (E2). Despite 
the sequence homology between the condensases KasA and KasB, they are predicted to 
participate in two different stages during the FAS II pathway: KasA may catalyze the first 
elongation steps (E1-FAS II) while KasB might be involved in the later steps (E2-FAS II), 
ultimately producing full-length mycolates with more than 40 carbon units [12, 13]. A rep-
resentation of matured α-mycolic acid is depicted in Figure 2B.
The meromycolate chain resulting from FAS II cycle can be “decorated” with chemical 
modifications such as cyclopropanations and methylations that are introduced before the 
second Claisen-type reaction occurs. These modifications can be at distal or proximal posi-
tions and are carried out by S-adenosyl-methionine (SAM)-dependent methyl transferases 
(Table 1). Unsaturations on the other hand, are proposed to occur differently under aero-
bic or anaerobic conditions. The method of double bond introduction in mycolic acid in 
Mtb, however, remains unclear. Under aerobic conditions, desaturases encoded by desA1, 
2, and 3 and other candidates such as Rv1371 are believed to complete the double bond 
introductions at the distal position, before the Claisen-type condensation take place. Under 
anaerobic conditions, unsaturations are believed to take place during the FAS II cycle in 
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the transition of the trans 2-enoyl intermediate to its 3-cis isomer in the distal position, 
resembling what FabM does in Streptococcus pneumoniae [13]. By sequence homology, this 
enzymatic reaction could be mediated by EchA10 and EchA11 in Mtb; however, there is not 
enough experimental evidence to support this hypothesis (Table 1). Finally, the oxygen-
ated mycolic acids (keto and methoxymycolic acids) have a common precursor (hydroxy-
mycolate) that is synthesized by the action of the SAM-dependent methoxymycolic acid 
synthase 4 (MmaA). The synthesis of methoxymycolic acid is additionally driven by the 
MmaA3 enzyme (Table 1) [12, 14].
After the modification in the meromycolate chain and the last condensation reaction occur, a 
mycolic acid (either α-, keto, or methoxymycolic acid) molecule is formed and can be attached 
to a trehalose molecule by the action of the Corynebacterineae mycolate reductase A, encoded 
by Rv2509 (also known CmrA) [15]. Once the mycolic acid is covalently linked with treha-
lose to form trehalose monomycolate (TMM), it is transported to the cell wall by the protein 
MmpL3 [16]. TMM is then the source of the mycolyl group for arabinogalactan and for other 
TMMs in the cell wall, generating trehalose dimycolate (TDM); in a reaction catalyzed by the 
fibronectin-binding proteins (Fbp) ABC ([17], reviewed in Refs. [14, 18]). Much of the under-
standing of the FAS I and II routes has been based on sequence homology with reference bacte-
rial strains and mutation analysis using model organism such as Mycobacterium smegmatis and 
Mycobacterium phlei. Despite the vast knowledge about the mycolic acid synthesis pathway, 
Figure 2. (A) Major operons involved in mycolic acid synthesis in Mtb. (B) Structure of an alpha-MA, the color represent 
the source of the carbon chain by either FAS I (light gray) or FAS II (black). P, proximal; D, distal.
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many unanswered questions remain regarding components of the FAS II pathway that are 
under current research [13].
2.3. Redox metabolism
In general, reduction-oxidation (i.e. redox) reactions are highly relevant for Mtb, since they not 
only comprise the necessary defence mechanisms developed to combat the host response dur-
ing the infection, but they are also part of its own bacterial metabolism [19]. Redox reactions 
could generate endogenous or exogenous stress for the bacteria. The endogenous redox stress 
is generated during aerobic or anaerobic respiration, where Mtb is exposed to reactive oxygen 
(ROI) and reactive nitrogen intermediates (RNI), generated when the bacterium uses oxygen 
and nitrogen as the final electron acceptor in the electron transport chain, respectively [20, 21]. 
RNI can be also generated when Mtb relies on glutamate metabolism for survival. During host-
infection, Mtb can experience a wide range of oxygen levels that can drastically alter its metab-
olism going from hyperoxic stress (when is in aerosol droplets) to low oxygen tension (during 
the intracellular phase in alveolar macrophages) to finally hypoxic to anoxic stress (in granu-
lomas). Additionally, inside the macrophage, Mtb is exposed to both ROI and RNI. Hydrogen 
peroxide (H
2
O
2
) and the superoxide radical (O−2) are the two most common ROI forms that 
are produced by macrophages and neutrophils to eliminate Mtb [22]. During hypoxic condi-
tions, the alteration in redox homeostasis leads to a higher NADH/NAD+ ratio which generate 
superoxide radicals that disrupt the redox balance in the cell. Consequently, enzymes with 
heme and sulfur complexes (i.e. cytochrome C, aconitase) can be severely affected. Therefore, 
the ability of Mtb to survive the redox stress from the host determines its success during the 
infection process. This stress has an impact on the bacterial metabolic pathways as well as on 
the expression of virulence factors [20, 21].
Intracellular or exogenously originated reactive oxygen species (ROS) and RNI have the poten-
tial to damage lipids, DNA, and proteins by oxidation, peroxidation, and nitration reactions [23], 
which can result in protein inactivation, and alteration of both cell organization and signal trans-
duction. Therefore, it is crucial to successfully maintain redox homeostasis to keep the integrity 
of the cell. Intracellularly, the changes in the redox and nutrient levels are sensed by WhiB pro-
teins (WhiB1-7) while extracellularly different molecules such as nitric oxide (NO), carbon mon-
oxide (CO), and H
2
O
2
. The reduced and oxidized forms of the nicotinamide adenine dinucleotide 
(NADH/NAD+) can work as sensors that induce a direct transcriptional response or indirectly 
alter transcription through a two-component regulatory system such as DosRS-DosRT [2, 21]. 
Moreover, different bacterial enzymes participate in the neutralization of the host-induced ROI 
and NOI such as superoxide dismutase (SodA), catalase-peroxidase (KatG), and the antioxidant 
complex formed by alkyl-hydroperoxidases (AhpC and AhpD), dihydrolipoamide acyltransfer-
ase (DlaT), and dehydrogenase (LpdC). Other enzymes in the redox metabolism include the 
peroxiredoxins (AhpE, TPx, Bcp, and BcpB) and thioredoxins (TrxA, B, and C).
Of these, KatG also plays a central role in Mtb resistance to INH. Mtb has only one single copy 
of katG with a coding sequence of 2223 base pairs (bp) generating a 704 amino acid protein 
with a molecular weight of approximately 80.6 kDa. KatG is presented as a dimeric haemopro-
tein that belongs to class I peroxidase superfamily, because of its high homology with yeast 
cytochrome C peroxidase [24]. KatG activates the prodrug INH, however its functions extends 
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beyond this activation. This enzyme is in fact one of the most important catalase-peroxidases 
that help the bacterium overcome external and internal redox stress. KatG possesses a mono-
functional catalase, broad-spectrum peroxidase, and peroxynitritase activity [25, 26]. The 
catalase-peroxidase activity is in the N-terminal domain of the protein that contains a heme-
binding motif, however, the C-terminus is also required for its catalytic function [24, 27]. KatG 
activity has also been associated with virulent Mtb strains, which are able to infect for longer 
periods and cause increased pathology in the host [28, 29].
As discussed above, redox reactions play an important role in bacterial respiration. In the next 
section, details about the cellular respiration process in Mtb are discussed. The relation with 
this topic and this chapter is based on the association of drug resistance mutations in impor-
tant genes such as katG. The mutations in these redox homeostasis genes possibly generate an 
alteration in the respiration complexes in Mtb as well.
2.4. Respiration in Mtb
Given the dynamic Mtb lifestyle, respiration in the bacterium should be highly adaptable. 
Specifically, during respiration, Mtb uses oxygen and other compounds (such as fumarate 
or nitrate) as the final electron acceptor depending on the specific bacterial metabolic status 
and the surrounding environment [30, 31]. The respiratory apparatus is responsible for gen-
erating ATP and reduced coenzymes (NADH and/or FADH
2
). Respiration is made possible 
by selected membrane-associated asymmetric complexes that allow for generation of proton 
motive force (PMF) and ATP, which are the major sources of energy in the cell. Different 
from other model organisms such as E. coli or Bacillus subtilis, Mtb obtains the majority of 
its ATP by the electron transport chain and the F
1
F
0
-ATP synthase machinery, with very 
little contributions from substrate level phosphorylation [31]. In fact, the ATP synthase is 
a recently successfully exploited target for developing anti-TB drugs of the drug class dia-
rylquinolines such as the recently described clinical drug bedaquiline [31, 32]. Specifically, 
diarylquinolines interact with the transmembrane subunit C of the ATP synthase machinery 
[33]. This again emphasizes the importance of ATP synthase machinery in the respiration 
process in Mtb.
Most of the Mtb enzymes/complexes involved in aerobic respiration have been identified and 
are composed primarily of two NADH dehydrogenases (NDH-1 and NDH-2) and two termi-
nal cytochrome oxidases (aa3-type cytochrome C oxidase and bd-type cytochrome oxidase). 
These enzymes participate in oxygen reduction and are coupled to generate the PMF that is 
used by the ATP synthase for the production of ATP. NDH-1 is encoded by the nuo operon 
(nuoA-N) and NDH-2 is present in two copies encoded by ndh and ndhA. Previous studies 
demonstrated that NDH-2 does not have a proton-translocating-function and is the main 
dehydrogenase in Mtb. NDH-2 reduces menaquinone to menaquinol that in turn can be oxi-
dized by one of the terminal aa3-type cytochrome C oxidase and bd-type cytochrome oxidase 
complexes. Because the bd-type cytochrome oxidase (CytA-B) is not coupled to proton pump-
ing, the direct oxidation of menaquinol by this oxidase is less energetically efficient compared 
to the aa3-type (CtaC-F). Instead, the oxidation of menaquinol can happen in a two-step pro-
cess with the participation of the cytochrome bc1 complex (QcrA-C) and the terminal aa3-type 
cytochrome oxidase (CtaC-F) with a higher energy yield [31, 32].
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Contrary to aerobic respiration, mediators in Mtb anaerobic respiration are poorly defined. 
However, in vitro hypoxic studies have allowed the identification of some important enzymes 
involved in this process. In a reduced-oxygen environment, the nitrate reductase (NarG-I), 
the nitrate transporter (NarK-2), and the NDH-2 dehydrogenase are upregulated. On the 
other hand, the ATP synthase subunits and the aa3-type cytochrome oxidase are downregu-
lated. During a low oxygen tension, the bd-type cytochrome oxidase is believed to be more 
utilized since it has a higher affinity for oxygen. ATP synthase is still active although at a 
lower membrane potential not commonly seen in other organisms, underlining the impor-
tance of PMF in keeping the bacterium alive during this metabolic state. This could be a regu-
lar scenario for Mtb inside the granuloma driving low metabolic activity with low or no Mtb 
growth (dormancy) [22]. Also, in the absence of oxygen, Mtb uses a set of reductases (such as 
succinate/fumarate reductase and nitrate reductase), hydrogenases (coupling H
2
 oxidation to 
respiration, encoded by Rv0082 and Rv0087), and ferredoxins (such as the encoded by fdxA) 
that preserve the PMF for bacterial survival [30, 31]. Other changes have been detected in 
anaerobic adaptation, for instance, the E1 subunit of the pyruvate dehydrogenase is upregu-
lated. Under anaerobic conditions, Mtb can stay alive but its growth is strongly reduced [31]. 
This theme is relevant because as it was previously described, there is a wide variety of oxygen 
tension in the Mtb interaction with the host.
2.5. Mtb envelope
Moving to another important aspect of Mtb physiology, the cell envelope of this bacterium 
has been the focus of research for many decades because of its distinct features, importance in 
bacterial pathogenicity, and the generation of the host immune response. The mycobacterial 
cell envelope is complex such that nutrients penetrate 10,000 times slower than they can do 
in the E. coli outer membrane [34]. Components of the cell envelope, particularly the enzymes 
that participate in their synthesis, have been recognized as possible drug targets. The under-
standing of the cell envelope is also required to design drugs that will be able to cross this 
impermeable barrier efficiently [35].
The Mtb envelope forms the interface between pathogen and host. From the outside to the 
inside, the Mtb cell envelope is composed of a layer of non-covalently linked glycolipids, pro-
teins, carbohydrates, and some lipids (the capsule), a covalently linked peptidoglycan layer 
that contains carbohydrates and lipids (the cell wall), and a plasmatic membrane (phospho-
lipid bilayer). In 1991, Minnikin proposed visualizing the lipid material in the Mtb envelope 
as two distinct membranes, analogous to a Gram-negative bacterium [36].
The most external layer of Mtb has been described as a “capsule” by some scientists. This layer 
contains mainly polysaccharides and a small amount of lipids (2–3%). The major capsular com-
ponent in slow growing mycobacteria, including Mtb is a glucan composed of repeating units 
of ->4-(-d-glucosyl residues substituted at position 6 with a mono- or oligoglucosyl residues). 
The capsular material also contains the heteropolysaccharide d-arabino-d-mannan and a man-
nan chain composed of ->6-(-d-mannosyl-1-> core with substitutions at some positions 2 with a 
(-d-mannosyl unit. Finally, the arabinomannan found in this extracellular material is “decorated” 
by other oligomannosides, which can be also secreted to the extracellular space [35], reviewed in 
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Ref. [37]. Glycolipids such as trehalose monomycolate (TMM) and trehalose dimycolate (TDM); 
phenolic lipids and glycopeptidolipids can be found in the outer part of the capsule and some 
of them are also cell wall-associated. TDM is also known as cord factor since it causes grow 
in “cords” in vitro. This particular glycolipid has been associated with the pathogenesis and 
immunogenicity of Mtb strains [38]. Lipoproteins such as LpqH (Rv3763), proteins such as Psts1 
(Rv0934) and the Ag85 complex (FbpA, Rv3804; FbpB, Rv1886; and FbpC, Rv0129) are also com-
monly found in the capsular material [35].
The Mtb cell wall has a covalently linked backbone with a collection of cell wall-associated 
lipids and polypeptides. The covalently linked molecules include peptidoglycan, arabinoga-
lactan, and mycolic acids. In addition to the presence of the last two biomolecules, there are 
two important hallmarks of the Mtb cell wall. First, the muramic acid is N-acylated, instead of 
N-acetylated as regularly observed in most eubacteria. Second, there are unusual cross-links 
between two chains of peptidoglycan that include bonds of two residues of diaminopimelic 
acid in addition to the usual d-alanyl-diaminopimelate linkage. Furthermore, mycolic acids 
represent about 40% of the cell wall [39, 40].
Mtb has a great variety of lipids that can be clustered into at least six lipid categories with 
around 2512 lipid groups [41]. Mycolic acids are the major constituent of the cell envelope. 
They were first named by Stodola and colleagues in 1938, who also depicted essential groups of 
their chemical structure. Mycolic acid structure was further defined by Asselineau in 1950 [42]. 
These are α-alkyl, β-hydroxyl, long-chain fatty acids that can be primarily covalently attached 
as esters of arabinogalactan in the cell wall or as “free lipids” in the capsule associated to tre-
halose in the TMM or TDM structures [12, 43]. Specifically, mycolic acids form an ester bound 
to the 5-position of the arabinose residue of the arabinogalactan [41]. Mycolic acids can also 
bind to glucose [44]. The covalently attached mycolic acids can be obtained by saponifica-
tion or methanolysis of the cell wall of the delipidated Mtb cells. Because mycolic acids are 
not soluble in methanol, they can be separated from moderately long-chain fatty acids with 
ether or chloroform solutions. Mycolic acids have one carbon chain bound to the hydroxyl 
group called the meromycolic chain and another (shorter) carbon chain that is bound to the 
α-carbon [35]. The synthesis of these molecules was previously discussed in Section 2.2.2 of 
this chapter.
Mycolic acids are not unique structures of the Mycobacterium genera, they can be present in 
Corynebacterium, Nocardia, and Rhodococcus. Mycolic acids from Mycobacterium are longer in 
carbon units (C70–C90) and have the largest meromycolic chain [39]. Additional modifications 
such as the introduction of cyclopropane rings in the meromycolate chain, unsaturations, eth-
ylenic groups, and methyl branches are also observed. Both cis and trans double bounds as 
well as cyclopropane rings can be found in the same type of mycolate. Some mycolic acids 
have additional oxygen functionality that is one feature used to classify them. These func-
tionalities are keto, methoxy, carboxy, and epoxy. Other types of mycolic acids lack of these 
oxygen groups, they are called α-mycolic acids and αʹ-mycolic acids. α and αʹ-mycolic acids 
differ in their chain length, αʹ-mycolic acids are shorter (usually of 60 carbon units) whereas 
α-mycolic acids contains more than 70 carbon units. α-mycolic acids represent more than 70% 
of the total mycolic acids found in Mtb, followed by keto and methoxy variants (15 and 10%). 
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The cyclopropane structures in this fatty acids contribute not only to its cell wall structure, but 
also protect the bacteria from oxidizing agents such as H
2
O
2
 (reviewed in Ref. [14]).
Finally, the plasmatic membrane includes different types of phospholipids such as phosphati-
dylglycerol, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylinositol man-
nosides (PIMs). PIMs are mainly located in the outer leaflet. Other important components are 
the highly immunogenic lipoglycan lipoarabinomannan (LAM) and lipomannan [39]. Due to 
the high abundance of LAM in the Mtb envelope, it has been tested as a biomarker for a point 
of care test with a wide range of sensitivity and specificity results in HIV-positive patients [45].
3. Mechanisms of drug resistance in Mtb
As is the case in other microorganisms, drug resistance in Mtb can be either intrinsic or 
acquired. Mtb cell wall structure and its low permeability are the major factors accounting for 
the high degree of intrinsic or natural tolerance to many antibiotics and other chemotherapeutic 
agents. Highly abundant mycolic acids in the cell wall reduce the cell permeability and create a 
crystalline-like structure after the cytosolic membrane. As seen in other mycobacterial species 
(especially in saprophytic species such as Mycobacterium chelonae), the more impermeable the 
cell wall, the more antimicrobial agents the mycobacteria can resist. Drugs such as sulphon-
amides, penicillin, tetracycline, and vancomycin are ineffective against Mtb. For vancomycin, 
this can explained because of its size and structure that do not allow its effective penetration 
through the Mtb “pseudo-outer membrane” [34]. However, recent findings demonstrated that 
Mycobacterium bovis and Mtb mutants lacking phthiocerol dimycocerosates are susceptible to 
glycopeptides such as vancomycin [46]. Additionally, the reduced number of porins in the Mtb 
“pseudo-outer membrane” possibly contributes to the intrinsic Mtb resistance against hydro-
philic compounds. Among other intrinsic factors, Mtb possess β-lactamase enzymes (encoded 
by blaC and blaS) that make this bacterium naturally resistant to β-lactams [2, 47]. For acquired 
drug resistance, spontaneous mutations in chromosomal genes during a suboptimal drug 
therapy are the most common cause for drug resistance in Mtb. Efflux mechanisms are less 
common but also present in these bacteria [47]. These intrinsic and acquired mechanisms have 
synergistic effects and make TB treatment particularly cumbersome.
Although a combined therapy for TB is normally effective for most cases, TB cases resistant 
to a subsection or all anti-TB drugs have been reported in clinical settings. Because INH and 
RIF are the most widely anti-TB drugs used, there is a higher frequency of mono-resistance 
to any of these drugs or to both drugs (INH and RIF, known as multidrug-resistance TB 
or MDR-TB) among drug-resistant Mtb strains. The study of drug-resistant TB has been an 
ongoing process, mainly because the understanding of the mechanism of action of several 
first line drugs (such as INH and pyrazinamide) has been subject of intensive research and 
controversies [48]. The cumulative exposure of Mtb strains to suboptimal concentrations of 
anti-TB drugs in an intermittent manner creates most of the acquired drug-resistant TB cases. 
In this way, many TB patients lose the best options for effective treatment from a disease that 
was initially curable.
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3.1. INH resistance
In 1951, the anti-TB properties of a new drug, INH, were reported. This was a critical event 
in TB history that was optimistically described as the “new treatment for the white scourge.” 
Unfortunately, the appearance of INH-resistant (INHr) cases emerged the same year INH 
was introduced in medical practice [49]. INH resistance is one of the most common forms of 
drug-resistant TB. The resistance mechanism to this drug is multigenic and can be divided 
into three categories: prevention of drug activation, alteration of the target, and differential 
expression of the target. In the first group, mutations in katG that prevent the activation of 
INH are present in the majority of resistant cases to this drug [50, 51]. Mtb strains with a full 
deletion of katG also fall into this category. KatG function was first correlated to INH resistance 
in 1953, when Middlebrook et al. discovered that INHr Mtb strains lacked catalase-peroxidase 
activity and were less virulent in guinea pigs [52]. The molecular validation of this observation 
was completed later by Zhang et al., restoring the sensitivity to INH in some Mtb resistant 
strains after the introduction of the katG gene from E. coli [53]. More than 60 years of chemo-
therapy with INH in TB cases has allowed the development of different Mtb genotypes of 
INH-resistant (INHr) profile and their associated phenotypes. Currently, there are more than 
300 known mutations in the katG gene alone associated with a wide range of minimum inhibi-
tory concentrations (0.2–256 mg/L) [51]. These mutations include missense mutations, inser-
tions, deletions, truncations, and full gene deletion. Depending on the position and nature 
of the mutation, katG mutants have different degrees of catalase-peroxidase activity [47, 51]. 
The mutation rate for the generation of INH-resistant strains is around 3.2 × 10−7 mutations/cell 
division (after exposure to 1 mg/L INH) in vitro [54–56] and presumably one in 108–9 organisms 
in vivo [57].
In the category of alteration of the target and increased expression of the target, mutations in 
the inhA gene or its promoter are accounted. InhA is the most commonly validated target for 
INH [49, 58]. Currently, around 15 mutations in the inhA gene have been identified in Mtb 
strains with low-level resistance to INH. inhA mutations also drive resistance to ethionamide 
(ETH), since INH and ETH share this enzyme as target [51]. The most studied mutation is 
the S94A that results in the reduction of the enzyme affinity for NADH and a reduced abil-
ity of INH-NAD adduct to inhibit the enzyme. Additionally, mutations in the inhA promoter 
that increase InhA levels have been also identified. Therefore, both the reduction in enzy-
matic activity, specifically KatG and the overexpression of the target (InhA) serve as resistance 
mechanisms against INH. Other mechanisms of INH resistance include the accumulation of 
NADH (by redox alteration) that binds InhA and protects it from the inhibitory effect of the 
INH-NAD adduct. An additional resistance mechanism includes acetylation of the drug by 
the nat encoded arylamine N-acetyl-transferase which prevents INH activation by KatG [59, 
60]. Finally, the drug efflux mechanisms include the participation of the protein EfpA, which 
is induced upon INH treatment [49]. It is important to describe that INH resistance in Mtb can 
be either low- or high-level when there is >1% of bacterial growth in the presence of 0.2 or 1 
μg/mL of INH, respectively. Regularly, mutations in the inhA promoter are linked to low-level 
of INH resistance while mutations in katG are associated with high-level of INH resistance in 
Mtb [61].
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3.2. RIF resistance
Followed the discovery of INH, rifampicin (RIF) was discovered in 1963 and reduced the anti-TB 
treatment from 18 to 9 months [62–64]. Currently, a shorter combined therapy with higher doses 
of rifampicin or isoniazid is being evaluated [65]. The rationale behind the increase dose of rifam-
picin is that the currently used dose of RIF was proposed in 1971 with the basis of generating a 
cost-effective treatment that was non-toxic for TB patients, albeit a study of the maximum dose 
of the drug tolerated in human has never been performed [66]. Recent studies in animal models 
have shown that higher doses of this drug could be effective even in shorter regimes, reducing 
also the probability to generate resistant microorganisms to the drug [66–68].
RIF resistance in Mtb is simpler than INH resistance. Up to date, mutations in one gene, rpoB, 
that encodes for the RNA polymerase β subunit and the target of the drug, are present in most 
of the RIF resistant (RIFr) cases. There are only four in the rpoB gene (N-terminus, and clusters 
I–III) where most of these mutations are found. In fact, mutations in an 81 base pair (27 codons) 
in the central region of cluster I, also known as the RIF resistance-determining region (RRDR), 
harbors more than 96% of all mutations associated with RIF resistance. Similarly to what is 
described for INH resistance, these mutations can be single amino acid substitutions, deletions, 
and insertions [62]. These mutations mainly affect the binding pocket where the drug interacts 
with the subunit of the polymerase. The most common amino acid substitutions observed in 
clinical RIFr strains include S531L and H526Y [69].
4. Impact of drug resistance in Mtb physiology as seen through 
proteomics perspective
Since there is a wider repertoire of INH resistance-conferring mutations compared with RIF 
resistance-conferring mutations (see Sections 3.1.1 and 3.1.2), a more variable phenotype in 
INHr strains compared to RIFr strains is expected. Additionally, the genetic lineage and back-
ground of each strain play an important role in the phenotype resultant after drug-resistance 
is acquired [69–71]. This is explained by the fact that compensatory mutations associated with 
some genetic backgrounds but not others may results in different competitive phenotypes. 
Our laboratory recently demonstrated that the same mutation causing INH resistance in 
two Mtb strains from different genetic lineages can result in different virulent phenotypes. 
Furthermore, these differences were associated with differences in protein levels of AhpC 
without any detectable mutation in the ahpC gene or its promoter. These Mtb strains were 
from different genetic lineages and exhibited a strongly different virulent profile in the mouse 
model of infection [72]. Therefore, following a “conservative approach,” comparing clinically 
relevant clonal or isogenic Mtb strains is crucial to understand the changes in Mtb physiology 
caused by drug resistance events. However, obtaining pure clonal pairs of Mtb derived from 
clinical settings is quite challenging.
Clonal Mtb pairs conceptually defines a pair or group of bacterial strains that share the same 
progenitor, but are generated after successive replication events with the possibility to develop 
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one or more single nucleotide polymorphisms (SNPs) each time, possibly due to external 
pressure such as drug exposure, oxygen tension among other factors [73]. The development 
of more discriminative and high-throughput genetic tools has allowed a more accurate char-
acterization of these clonal and isogenic strains. Isogenic and clonal strains are difficult to 
obtain from clinical cases due to the possibility of infection with different clones of Mtb, espe-
cially in high burden TB countries such as India and South Africa [74]. Furthermore, most 
settings with high burdens of TB do not routinely perform whole genome sequencing and are 
not equipped to carry a biobank of Mtb isolates. In the next sections, we will explore specific 
examples of Mtb strains that experienced compensatory physiological events after acquiring 
INH and/or RIF resistance comparing them to their clonal or isogenic parental strain.
We have used comparative shotgun proteomics of different Mtb cellular fractions to describe 
different aspects of the Mtb physiology in vitro and in vivo, including the effects of drug 
resistance-conferring mutations in the new bacterial phenotype [75–82]. The advantage of 
evaluating differences in protein abundance at each cellular fraction allows confirming if 
any differences seen are due to a global redistribution of protein levels or if changes in pro-
tein abundance are instead associated with a specific compartmentalization of the protein. 
After the elucidation of the genome of many organisms, proteomics emerged as a power-
ful methodology that not only describes the sequence, structure, and function of the pro-
teins, but also extends to the analysis of complex mixture of proteins using high-throughput 
techniques [83, 84]. Proteomics analyze mature proteins considering all the complex post-
translational events that occur in the cell and that finally represent the bacterial phenotype. 
As it was stated by LaBaer in 2011, “proteins provide the verbs to biology” [85, 86], and pro-
teomics allow for naming different biological events [87]. As the proteome of the cell variate 
parallel to internal metabolic variation and external cues, proteomics is considered the most 
direct scaffold to measure cell activity [86]. Mass spectrometry (MS)-based technologies are 
central components of the protein analysis. These methods include shotgun and targeted 
proteomics that have different modes for acquiring mass spectra. Shotgun proteomics, a 
term coined by John Yates III and his laboratory, offers an indirect measurement of pro-
teins through peptides derived from their enzymatic digestion [84]. Shotgun proteomics, 
also known as discovery proteomics, uses liquid chromatography (LC) connected to tandem 
MS (MS/MS) for the identification of the protein components in the sample. The protein 
identification is based on the determination of the amino acid sequence which is achieved by 
comparing the experimental tandem mass spectra with the theoretical tandem mass spectra 
generated from an in silico digestion of a protein database.
4.1. “The isoniazid resistance case”: findings from katG mutant Mtb strain of the Beijing 
lineage through proteomics
Given the high frequency of katG mutations among INHr Mtb strains, this section will focus 
on the proteomics findings that were revealed in the study of an isogenic pair of the Beijing 
lineage after acquisition of drug resistance due to a katG mutation [80]. As the starting point, 
it should be noted that early studies revealed that INHr Mtb strains with katG mutations have 
different levels of the enzyme and a different degree of alteration of its catalase or peroxidase 
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activities [88]. These mutations have also different impact in the virulence and fitness of the 
INHr bacterium. However, to our knowledge, the study described here is unique as it used 
clinical isogenic pairs of Mtb strains resulting from katG mutations and associated with an 
INHr profile.
Consistent with previous studies, the global proteomics study of the Beijing clinical pair 
through LC-MS/MS demonstrated that the INHr strain had significantly reduced levels of 
KatG in three of the four subcellular fractions evaluated compared with its isogenic INHs pro-
genitor. The fact that the levels of this protein were reduced in the soluble fractions (cytosol 
and secreted proteins) and the bacterial membrane is a clear indication that this INHr strain 
lacks its ability to activate INH. An additional 45 proteins were found with altered abundance; 
these protein changes may be a potential compensatory mechanisms related to the reduced 
KatG levels and its consequent impact on mycobacterial physiology and fitness [80].
Among the 45 proteins identified, proteins related to intermediary metabolism and respira-
tion represented majority of differentially abundant between INHr and INHs strains. Among 
them, enzymes from the tricarboxylic acid (TCA) cycle (SucC, SucD, Mdh, Acn, and AceE) 
were all decreased in the INHr strain. Proteins related to lipid biosynthesis and degradation 
pathways also represented important differences between the strains, with mainly higher lev-
els in the INHr strain. The proteins Fas, FabG4, and FbpD of the lipid biosynthetic pathway 
were increased. In the β-oxidation pathway, the dehydrogenases FadE22 and FadE32 and the 
acetyl-CoA acyltransferase FadA2 were increased, but the crotonases EchA9 and EchA21 were 
decreased in the INHr strain. Proteins in the virulence and detoxification category such DnaK 
and GroES were also increased in the INHr strain as well as the hypothetical protein Rv2204c. 
Finally, the transcription regulation proteins Crp and PrrA were also higher in the INHr strain 
compared to the INHs parental strain [80].
Interestingly, the INHr Beijing strain had the katG mutation L101R (identified in the INHr 
by whole genome sequencing) [89]. However, this katG mutation was not very stable for the 
Beijing INHr strain, which after successive passes reversed to the wild type genotype and 
INHs phenotype. A previous report of an INHr reversion in Mtb was observed in a katG 
mutant in the absence of the drug pressure [90]. Based on these reports, it is possible that 
not only the resistant-conferring mutations can result in a distinctive phenotype but also 
that these mutations are not easily conserved in the Mtb genome after removing the pres-
sure that originates them.
A previous proteomic analysis using non-clonal Mtb strains found five proteins overex-
pressed in the INHr strains comparing whole cell lysates. These proteins were found through 
two-dimensional (2D) gel electrophoresis and matrix-assisted laser desorption ionization 
time of flight-MS (MALDI-TOF) and include OpcA, FixB, RegX3, a probable oxidoreductase 
(Rv2971), and Wag31. Most of these proteins were involved in cellular metabolism, includ-
ing redox metabolism (such as OpcA, Rv2971, and FixB) and there was one transcriptional 
regulatory protein (RegX3). These proteins are not related to any of the known INH-resistance 
mechanisms and were not observed in the previous clonal study. However, they still confirm 
the alteration of proteins involved in redox stress and energetic metabolism [91].
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A recent virulence study of laboratory and clinical clonal pairs of Mtb from the T lineage and 
with different susceptibility profiles to INH also showed an important reduction of the KatG 
protein in the INHr strains. Associated with this KatG reduction, this study revealed a variable 
alkyl-peroxidase C (AhpC) response in the INHr strains which was dependant on the genetic 
background. Although both clinically and laboratory-derived INHr Mtb strains had reduced 
levels of KatG, western blot analysis with anti-AhpC demonstrated that the laboratory INHr 
strain had increased levels of AhpC while the clinical INHr strain had reduced levels of AhpC 
compared to their clonal parental strain, respectively. The difference observed in the AhpC 
levels was also translated in a non-significant reduction of the virulence in the laboratory INHr 
contrasting the strongly significantly reduced virulent profile for the clinical INHr strain [72]. 
A more robust proteomics study trough LC-MS/MS is being developed to reveal more insights 
about the proteomics differences among this clinical and laboratory-derived clonal pairs.
4.2. Acquisition of rifampicin (RIF) resistance in isogenic Mtb strains of the Beijing and 
Haarlem lineage
Phenotypic consequences of mutations in the rpoB gene associated with RIF resistance are 
understudied in Mtb. However in recent years, this theme has gained interest given the associ-
ation of rpoB mutations with a variety of phenotypes in other microorganisms. For instance, in 
E. coli, rpoB mutations mimic the “stringent” response that is usually driven by ppGpp under 
stress conditions [92]. In B. subtilis and Streptomyces coelicolor, rpoB mutations are associated 
with an increased antibiotic production and increased production of other metabolites [93–95]. 
In Neisseria meningitidis and Staphylococcus aureus, rpoB mutations lead to a decrease perme-
ability of the cell wall, which can be related to a subsequent increase in tolerance to certain 
antibiotics such as vancomycin [96–98]. Interestingly, after exposure to RIF, Mtb also appears 
to have an increased tolerance to ofloxacin, probably because of an increase activity of efflux 
pumps [99], although recent findings from our laboratory as well as others also suggest a 
potential role for cell permeability [75, 100]. In our study, isogenic Mtb pairs with two different 
rpoB mutations and representing two different genetic lineages (Beijing and Haarlem) showed 
an increased abundance of proteins involved polyketide synthesis. Proteomics findings were 
confirmed by an independent transcriptomics analysis of the strains grown intracellularly in 
in vitro macrophages. Both RIFr rpoB mutants revealed significant increased expression of mul-
tifunctional enzymes of the phenolpthiocerol synthesis type I polyketide synthase PpsE and C, 
which are involved in the biosynthesis of phthiocerol dimycocerosate (PDIM) and other lipids 
in Mtb [75]. We also observed a significantly increased abundance of the ABC transporter drrA, 
which has homology with other daunorubicin efflux pumps, but it is also implicated in export 
of PDIM across the cell membrane [101, 102]. Both increased abundance in lipids, as well as 
potential increase in efflux pump activity may result in accumulative reduction of cell perme-
ability and may have important implications in subsequent acquisition of drug resistance.
4.3. Study of multidrug resistance in Mtb trough proteomics
A handful of proteomic studies focused on the comparison of drug susceptible (DS) versus 
multidrug-resistant strains (MDR) Mtb strains are available in the literature [70, 103–107]. 
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Although these studies analyze clinical DS and MDR Mtb strains, the majority of them were 
comparing either non-related strains or strains with specific different genetic lineage. For 
instance, one study included H37Rv and H37Ra in the comparison and other compared DS 
Central-Asian (CAS)-2 with MDR East-African Indian (EAI)-3 strains [104]. The latter did 
not allow the study of the MDR phenotype under the same genetic background. There was 
one study that evaluated Mtb strains isolated from one single patient after many treatment 
failure episodes. Here, we will explore the findings specifically related to the DS and the first 
MDR strain isolated, since the next Mtb strains were also resistant to kanamycin. The MDR 
strain of the CAS 1-Delhi genotype had increased levels of 10 proteins through 2D electro-
phoresis and MALDI-TOF compared to its DS clonal pair. These proteins include chapero-
nin Hsp70, bacterioferritin BfrA, mycolyl-transferase FbpD, a component of the translational 
apparatus GatA, the phosphoserine aminotransferase SerC, Wag31, and the hypothetical 
proteins Rv1827, Rv2204c, Rv0543c, and Rv2004c [103]. Interestingly increased levels of 
FbpD and Rv2204c were also found in the INHr study of Beijing lineage [80]. Similarly, pro-
tein Wag31 was increased in a previous proteomic study monoresistant Mtb strains.
The proteomic analysis of non-genetically related Mtb strains revealed commonly increased 
levels of GroEL2, DlaT, ESAT-6, and conserved protein Rv3699 in the MDR strains compared 
to DS strains [70, 105–107]. Similar to the previous INHr proteomics studies mentioned above, 
some studies showed increased levels of FadA2, FabG4, BfrA, GroES, FixB, Rv2971, OpcA as 
well as lower levels of Mpt63 in MDR versus DS Mtb strains. However, there were contrasting 
levels of the proteins Mdh and SahH among the MDR studies and also discrepant tenden-
cies of Fas in MDR strains compared to the INHr study of the Beijing genotype. On the other 
hand, there was one study that found increased levels of PpsC in a MDR strain compared to 
H37Rv as it was described in the RIF resistance proteomics study of isogenic pairs of Beijing 
and Haarlem genotype.
The analysis using non-genetically related strains provide valuable insights about the protein 
dynamics among DS and MDR Mtb strains. However, the fact that proteins such as the cat-
alase-peroxidase KatG are increased in MDR strains without establishing the INH-resistance 
mechanism [104, 107], generates some questions such as: Is this protein increase because some 
genotypes express constitutively more KatG? According to this, it is not possible to conclude that 
there are actually INHr strains that have increased levels of KatG and highlight the necessity of 
study the drug resistance event under the same genetic background.
5. Lipidomics studies in Mtb drug-resistant strains
5.1. Lipidomics in INHr Mtb strains
Among the different scientific disciplines supporting biological research, metabolomics is the 
study of chemically diverse groups of biomolecules including sugars, nucleotides, peptides, 
lipids, among others; using technologies such as MS and nuclear magnetic resonance (NMR). 
Lipidomics is a branch of metabolomics that specializes on the water-insoluble metabolites—
lipids. These are diverse metabolites that are part of the major molecules in the cell (particu-
larly, in the cell membrane) [108]. In Mtb, lipids are a very relevant group of molecules, since 
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at it has been previously discussed, they are responsible for the intrinsic-drug-resistant nature 
against some antibiotics, and its synthesis has been the target of some anti-TB drugs (INH and 
ETH). Consistent with this idea, it is plausible to think that the study of the Mtb lipid is an 
important part of the description of drug-resistant Mtb strains.
Thus far, only one metabolomics study has been reported comparing katG mutant-INHr 
strains derived from a drug susceptible parental strain of the Haarlem genotype. Through 
2D-gas chromatography-TOF MS, this study showed increased levels of saturated fatty acids 
(FA) in the INHr strains; particularly saturated FA with 16–20-carbon chain compared with its 
wild type that could be as a result of the oxidative stress which makes the bacteria rely on the 
β-oxidation of fatty acids as a carbon and energy source [109].
5.2. Lipidomics in RIFr Mtb strains
The lipidomics studies in RIF resistant Mtb have been focused on the RIF resistant strains that 
are both laboratory and clinically isolated. The laboratory-derived W-Beijing and CDC1551 
were used as the parental DS strains and were exposed to 2 ug/mL RIF to select for the RIFr 
strains. In this way, three different rpoB mutants (S531L, Q513E, and H526Y for each Mtb strain) 
were studied. The analysis revealed reduced levels of di-acylated sulfoglycolipid (Ac2SGL) and 
mycobactins (including carboxymycobactins), while increased levels of PDIM compared to 
their DS parental strain. These compounds were identified among 172 features in the W-Beijing 
group and 102 features in the CDC1551 group analyzed by high performance liquid chromatog-
raphy (HPLC) mass quadrupole-time-of-flight (QTOF) MS and suggesting a global remodeling 
of the cell wall after acquisition of RIF resistance [100]. This study supports previous findings 
from our group, which included a significant increase of diacylglycerol phosphocholines and 
PDIM precursors as observed by ultra-performance liquid chromatography (UPLC)-QTOF [75].
6. Closing remarks
The systematic study of Mtb phenotype, its proteome and metabolome (including, but not 
limited to lipidome) permits a functional description of how Mtb adapts, and sometimes 
thrives, under intrinsic (i.e. host response) and extrinsic pressure (i.e. exposure to drugs). 
These types of studies help to resolve not only the features of drug-resistant strains, but also 
contribute to the discovery of the facile and specific detection of biomarkers of drug resistance 
and ultimately contribute to the discovery of new targets for these Mtb strains that are hard to 
eliminate and often result in poor clinical outcomes for those infected.
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